Banque Cantonale Vaudoise Has $2.12 Million Holdings in Biogen Inc. $BIIB

Banque Cantonale Vaudoise reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 18.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,145 shares of the biotechnology company’s stock after selling 3,335 shares during the period. Banque Cantonale Vaudoise’s holdings in Biogen were worth $2,122,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Biogen in the 2nd quarter valued at about $284,358,000. Orion Porfolio Solutions LLC increased its holdings in Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Biogen by 190.7% in the second quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock valued at $78,415,000 after buying an additional 409,591 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Biogen by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock worth $2,171,533,000 after buying an additional 257,812 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in shares of Biogen by 49.5% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 671,054 shares of the biotechnology company’s stock worth $94,001,000 after buying an additional 222,297 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on BIIB shares. The Goldman Sachs Group reissued a “buy” rating on shares of Biogen in a research note on Monday, February 9th. Wolfe Research set a $231.00 price objective on shares of Biogen in a report on Monday, February 9th. Mizuho increased their price objective on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. TD Cowen raised their target price on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, BMO Capital Markets boosted their target price on Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research report on Friday, February 6th. Twelve research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $205.04.

Biogen Stock Performance

Shares of BIIB opened at $190.48 on Thursday. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The stock’s fifty day moving average price is $183.84 and its two-hundred day moving average price is $166.32. The firm has a market cap of $27.95 billion, a PE ratio of 21.62, a PEG ratio of 1.50 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the company posted $3.44 EPS. Biogen’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities research analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

Insider Buying and Selling at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.18% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen presented additional Phase 1b data for salanersen in spinal muscular atrophy (SMA) showing new motor milestones, a supportive safety profile over one year, and the launch of a global Phase 3 program — news that increases the drug’s commercial and clinical probability upside. GlobeNewsWire: Salanersen Phase 1b
• Positive Sentiment: Additional media coverage emphasizes salanersen’s once-yearly dosing potential and the potential to address patients with suboptimal response to prior gene therapy — a clear positive for BIIB’s late-stage pipeline narrative. The Pharma Letter: Salanersen data
• Positive Sentiment: Analyst and market commentary is supportive: a Barchart piece notes BIIB is outperforming the healthcare sector, and Zacks highlights BIIB as a strong value stock — both reinforce investor sentiment and may attract relative-value and sector-rotation flows. Barchart: BIIB outperforming Zacks: Value case
• Positive Sentiment: Macro/market commentary from industry voices (Josh Brown) argues large-cap biotech is “growth without disruption risk,” which can boost investor appetite for established biotech names like BIIB. Josh Brown / 247wallst
• Neutral Sentiment: Biogen’s presentation transcript from the Leerink Global Healthcare Conference is available; such presentations can clarify near-term strategy but typically have incremental impact unless new guidance/data are revealed. Seeking Alpha: Leerink transcript
• Neutral Sentiment: Coverage summarizing Q4 winners/losers versus peers provides context on relative performance but did not report a new catalyst specific to Biogen. Yahoo Finance: Q4 winners & losers
• Neutral Sentiment: Short-interest entries in the feed show contradictory/erroneous values (zeros and NaN); there’s no reliable evidence here of a material increase in short-selling pressure.
• Neutral Sentiment: An article about a biogenic carbon removal project (Svante) appears unrelated to Biogen the biotech and is unlikely to affect BIIB’s stock. Financial Post: Svante CDR project

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.